lidorestat has been researched along with Chronic Illness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dicioccio, AT; Geraci, LS; Gunn, DE; Jacot, JL; Jones, JH; Jones, ML; Mitschler, A; Petrova, T; Podjarny, AD; Sawicki, DR; Sredy, J; Van Zandt, MC | 1 |
| Doan, B; Podjarny, AD; Sawicki, DR; Sredy, J; Van Zandt, MC | 1 |
2 other study(ies) available for lidorestat and Chronic Illness
| Article | Year |
|---|---|
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
Topics: Aldehyde Reductase; Animals; Cataract; Chronic Disease; Crystallography, X-Ray; Diabetes Complications; Diabetes Mellitus, Experimental; Humans; Indoleacetic Acids; Lens, Crystalline; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Structure-Activity Relationship; Thiazoles; Tissue Distribution | 2005 |
Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
Topics: Acetates; Aldehyde Reductase; Benzothiazoles; Catalytic Domain; Chronic Disease; Computer Simulation; Crystallography, X-Ray; Diabetes Complications; Enzyme Inhibitors; Humans; Inhibitory Concentration 50 | 2009 |